Letrozol Sandoz (Letrozole)

Letrozol Sandoz is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. It works within the hormone‑driven pathway to reduce circulating estrogen.

• Hormone receptor‑positive breast cancer (postmenopausal): Decreases estrogen levels to inhibit tumor proliferation.
• Adjuvant therapy for early‑stage breast cancer: Helps prevent disease recurrence after surgery.
• Metastatic breast cancer (postmenopausal): Provides disease control when cancer has spread beyond the breast.

• Letrozole selectively inhibits the aromatase enzyme, which converts adrenal and peripheral androgens into estrogens. By blocking this conversion, systemic estrogen concentrations fall, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing or halting cancer progression.

Letrozol Sandoz may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Hot flashes: Sudden feeling of warmth, often with sweating.
• Joint and muscle pain: Arthralgia or myalgia affecting daily activities.
• Fatigue: Persistent tiredness not relieved by rest.
• Nausea: Mild to moderate upset stomach.
• Headache: Tension‑type or throbbing pain.
• Dizziness: Light‑headed sensation, especially on standing.

Serious or Rare Side Effects

• Severe liver injury: Jaundice, dark urine, or elevated liver enzymes.
• Bone fractures: Increased risk of osteoporosis‑related breaks.
• Pulmonary embolism: Sudden shortness of breath, chest pain, or coughing up blood.
• Allergic reactions: Rash, swelling, or anaphylaxis.
• Elevated cholesterol: Significant rise in LDL levels.
• QT interval prolongation: Potential cardiac rhythm disturbances.

Before initiating Letrozol Sandoz, clinicians should evaluate patient history and monitor specific parameters.

• Bone health assessment: Perform baseline bone mineral density testing and consider calcium/vitamin D supplementation.
• Liver function monitoring: Check hepatic enzymes periodically during therapy.
• Cardiovascular risk: Assess lipid profile and manage hypercholesterolemia as needed.
• Pregnancy and lactation: Contraindicated; ensure effective contraception in women of child‑bearing potential.
• Store at ambient temperature: Keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Letrozol Sandoz can interact with other medicines that affect estrogen pathways or CYP enzymes.

Major Interactions (Avoid)

• Estrogen‑containing hormone therapy: Counteracts the drug’s estrogen‑lowering effect.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May markedly reduce letrozole plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP2A6 or CYP3A4 inhibitors (e.g., fluconazole, ketoconazole): May increase exposure and risk of toxicity.
• Warfarin: Potential for altered anticoagulant effect; monitor INR.
• Cholesterol‑lowering agents (e.g., statins): May require lipid monitoring due to possible additive effects on cholesterol levels.